On September 12, 2023, Adelene Perkins, a director at Infinity Pharmaceuticals Inc, sold 410,196 shares of the company. This move has sparked interest among investors and analysts alike, as insider trading activities often provide valuable insights into a company's prospects.

• Warning! GuruFocus has detected 3 Warning Signs with INFI. Click here to check it out.
• INFI 30-Year Financial Data
• The intrinsic value of INFI

Adelene Perkins is a seasoned executive with a wealth of experience in the pharmaceutical industry. She has been a director at Infinity Pharmaceuticals Inc, a biopharmaceutical company that develops novel medicines for people with cancer, for several years. Her insider trading activities, therefore, carry significant weight and are closely watched by market participants.

Infinity Pharmaceuticals Inc is a biopharmaceutical company that is engaged in discovering, developing, and delivering medicines for people with cancer. The company's product portfolio includes IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma).

Over the past year, the insider has sold a total of 410,196 shares and has not made any purchases. This trend is illustrated in the following image:

The insider's selling activities coincide with a period of low stock price for Infinity Pharmaceuticals Inc. On the day of the insider's recent sale, the shares were trading at $0.07 each, giving the company a market cap of just over $4 million.

The company's low stock price relative to its GF Value suggests that it may be undervalued. The GF Value, an intrinsic value estimate developed by GuruFocus, is calculated based on historical multiples, a GuruFocus adjustment factor, and future business performance estimates from Morningstar analysts. The GF Value for Infinity Pharmaceuticals Inc is $1.22, and the price-to-GF-Value ratio is 0.06. This indicates that the stock may be a possible value trap, and investors should think twice before investing.

The insider's selling activities, coupled with the company's low stock price and possible value trap status, suggest that investors should approach Infinity Pharmaceuticals Inc with caution. While the insider's selling activities do not necessarily indicate a negative outlook for the company, they do warrant careful consideration.

As always, investors are advised to conduct their own thorough research before making any investment decisions.